MBX Biosciences Q2 FY26 net loss widens to $37.1 million; R&D expenses rise to $31 million
MBX•Q2 loss widens as development spending rises
MBX Biosciences posted a Q2 net loss of $37.1 million, widening from $19.4 million a year earlier.
- R&D expense rose 75.14% to $31 million, due to canvuparatide Phase 3 start-up costs and ongoing canvuparatide and MBX 4291 trials.
- G&A expense more than doubled to $9.9 million on higher personnel-related costs tied to expansion of leadership and infrastructure.
- Cash, cash equivalents and marketable securities totaled $418.6 million at June 30; management expects funding to last into 2029.
- The Phase 3 canvuparatide trial is recruiting for a Q3 start; CEO Steve Hoerter highlighted early MBX 4291 data supporting once-monthly dosing.
